Contamination of Brexafemme with a non-antibacterial beta-lactam drug could lead to reactions such as swelling, rash, urticaria and anaphylaxis.
Scynexis is recalling two lots of Brexafemme (ibrexafungerp) because of the potential for cross-contamination. Brexafemme is a non-azole antifungal approved to treat and prevent recurrent vaginal yeast infections. It is the only treatment for vaginal yeast infections that is both oral and non-azole. It has broad activity on a range of Candida species, including azole-resistant strains.
During a review of manufacturing equipment at a supplier, it was discovered there could be potential cross-contamination with a non-antibacterial beta-lactam drug. This could lead to reactions such as swelling, rash, urticaria and anaphylaxis. To date, Scynexis has not received any reports of adverse events because of possible beta-lactam cross contamination.
Brexafemme is packaged in blister packs with four 150-mg tablets (NDC 75788-115-04). The affected lots include the following lots include LF21000008 with an expiration date of November 2023 and LF22000051 with an expiration date of November 2025. The recalled lots were distributed nationwide to wholesalers across the United States beginning in December 2022.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More